Chimera protein comprising FVIII and vWF factors, and use thereof
US11046749B2 · kind B2 · utility
0Cited by
5References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 23, 2017 |
| Grant date | Jun 29, 2021 |
| Priority date | — |
| Expiry date | Aug 4, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/50
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A chimera protein according to the present application has a significantly increased in vivo half-life when administered because of a vWF domain coupled to FVIII, such that when used as a hemophilia A therapeutic agent, convenience for patients can be increased and medical expenses can be reduced.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.